How should patients with dyslipidaemia be monitored?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1652, 2008-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Once Daily Aminoglycoside Therapy: Is It Less Toxic Than Multiple Daily Doses and How Should It Be Monitored?

By Barclay M.L. Kirkpatrick C.M.J. Begg E.J.

Clinical Pharmacokinetics, Vol. 36, Iss. 2, 1999-02 ,pp. : 89-98

Adis International

Access to resources Recommend Favorite

How should epilepsy in elderly patients be treated?

Inpharma, Vol. 1, Iss. 1235, 2000-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Pharmacoresistance in Epilepsy: How Should It Be Defined?

By Perucca E.

CNS Drugs, Vol. 10, Iss. 3, 1998-09 ,pp. : 171-179

Adis International

Access to resources Recommend Favorite

How should TNF inhibitors be used in rheumatoid arthritis?

Inpharma, Vol. 1, Iss. 1250, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

How much should we be willing to pay?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 554, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite